Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Galina Tsykunova, Håkon Reikvam, Aymen Bushra Ahmed, Ina Nepstad, Bjørn Tore Gjertsen & Øystein Bruserud. (2012) Targeting of polo-like kinases and their cross talk with Aurora kinases – possible therapeutic strategies in human acute myeloid leukemia?. Expert Opinion on Investigational Drugs 21:5, pages 587-603.
Read now
Read now
Kimberley Joanne Hatfield, Philippe Lassalle, Rafael Alexander Leiva, Roald Lindås, Øystein Wendelboe & Øystein Bruserud. (2011) Serum levels of endothelium-derived endocan are increased in
patients with untreated acute myeloid leukemia. Hematology 16:6, pages 351-356.
Read now
Read now
Hanne Fredly, Camilla Stapnes Bjørnsen, Bjørn Tore Gjertsen & Øystein Bruserud. (2010) Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukaemia – a report of five cases. Hematology 15:5, pages 338-343.
Read now
Read now
Camilla Stapnes, Bjørn Tore Gjertsen, Håkon Reikvam & Øystein Bruserud. (2009) Targeted therapy in acute myeloid leukaemia: current status and future directions. Expert Opinion on Investigational Drugs 18:4, pages 433-455.
Read now
Read now
Anita Ryningen, Camilla Stapnes, Kristin Paulsen, Philippe Lassalle, Bjørn Tore Gjertsen & Øystein Bruserud. (2008) In vivo biological effects of ATRA in the treatment of AML. Expert Opinion on Investigational Drugs 17:11, pages 1623-1633.
Read now
Read now
Hanne Hagland, Julie Nikolaisen, Linn I Hodneland, Bjøorn T Gjertsen, Øystein Bruserud & Karl J Tronstad. (2007) Targeting mitochondria in the treatment of human cancer: a coordinated attack against cancer cell energy metabolism and signalling. Expert Opinion on Therapeutic Targets 11:8, pages 1055-1069.
Read now
Read now
Articles from other publishers (32)
Tej K Pandita, Clayton R. Hunt, Vipin Singh, Santanu Adhikary, Shruti Pandita, Siddhartha Roy, Kenneth Ramos & Chandrima Das. 2022. Metabolism and Epigenetic Regulation: Implications in Cancer. Metabolism and Epigenetic Regulation: Implications in Cancer
115
141
.
Guanya Li, Dunhui Li, Tao Wang & Shanping He. (2021) Pyrimidine Biosynthetic Enzyme CAD: Its Function, Regulation, and Diagnostic Potential. International Journal of Molecular Sciences 22:19, pages 10253.
Crossref
Crossref
Yu Bai, Daid Ahmad, Ting Wang, Guihua Cui & Wenliang Li. (2019) Research Advances in the Use of Histone Deacetylase Inhibitors for Epigenetic Targeting of Cancer. Current Topics in Medicinal Chemistry 19:12, pages 995-1004.
Crossref
Crossref
Joanna Zabkiewicz, Marie Gilmour, Robert Hills, Pares Vyas, Elizabeth Bone, Alan Davidson, Alan Burnett & Steven Knapper. (2016)
The targeted histone deacetylase inhibitor tefinostat (CHR-2845) shows selective
in vitro
efficacy in monocytoid-lineage leukaemias
. Oncotarget 7:13, pages 16650-16662.
Crossref
Crossref
Nicola A. Philbrook & Louise M. Winn. (2015) Investigating the effects of in utero benzene exposure on epigenetic modifications in maternal and fetal CD-1 mice. Toxicology and Applied Pharmacology 289:1, pages 12-19.
Crossref
Crossref
Giedre Valiuliene, Ieva Stirblyte, Dovile Cicenaite, Algirdas Kaupinis, Mindaugas Valius & Ruta Navakauskiene. (2015)
Belinostat, a potent HDACi, exerts antileukaemic effect in human acute promyelocytic leukaemia cells
via
chromatin remodelling
. Journal of Cellular and Molecular Medicine 19:7, pages 1742-1755.
Crossref
Crossref
Kristy R. StengelScott W. Hiebert. (2015) Class I HDACs Affect DNA Replication, Repair, and Chromatin Structure: Implications for Cancer Therapy. Antioxidants & Redox Signaling 23:1, pages 51-65.
Crossref
Crossref
Xiao-Jian Sun, Na Man, Yurong Tan, Stephen D. Nimer & Lan Wang. (2015) The Role of Histone Acetyltransferases in Normal and Malignant Hematopoiesis. Frontiers in Oncology 5.
Crossref
Crossref
Ingvild Haaland, Jill A Opsahl, Frode S Berven, Håkon Reikvam, Hanne K Fredly, Ragnhild Haugse, Bernd Thiede, Emmet McCormack, Sonia Lain, Øystein Bruserud & Bjørn Tore Gjertsen. (2014) Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia. Molecular Cancer 13:1.
Crossref
Crossref
Jurate Savickiene, Grazina Treigyte, Giedre Valiuliene, Ieva Stirblyte & Ruta Navakauskiene. (2014) Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone deacetylase inhibitor belinostat in human acute promyelocytic leukemia cells. Anti-Cancer Drugs 25:8, pages 938-949.
Crossref
Crossref
Punit Prasad, Michelle RönnerbladErik Arner, Masayoshi Itoh, Hideya Kawaji, Timo Lassmann, Carsten O. Daub, Alistair R. R. Forrest, Andreas LennartssonKarl Ekwall. (2014) High-throughput transcription profiling identifies putative epigenetic regulators of hematopoiesis. Blood 123:17, pages e46-e57.
Crossref
Crossref
Hilde Kvestad, Lasse Evensen, James B. Lorens, Øystein Bruserud & Kimberley J. Hatfield. (2014)
In Vitro
Characterization of Valproic Acid, ATRA, and Cytarabine Used for Disease-Stabilization in Human Acute Myeloid Leukemia:
Antiproliferative Effects of Drugs on Endothelial and Osteoblastic Cells and Altered Release of Angioregulatory Mediators by Endothelial Cells
. Leukemia Research and Treatment 2014, pages 1-12.
Crossref
Crossref
Hanne Fredly, Elisabeth Ersvær, Astrid Olsnes Kittang, Galina Tsykunova, Bjørn Tore Gjertsen & Øystein Bruserud. (2013) The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia. Clinical Epigenetics 5:1.
Crossref
Crossref
Hanne Fredly, Bjørn Tore Gjertsen & Øystein Bruserud. (2013) Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents. Clinical Epigenetics 5:1.
Crossref
Crossref
A Mims, A R Walker, X Huang, J Sun, H Wang, R Santhanam, A M Dorrance, C Walker, P Hoellerbauer, S S Tarighat, K K Chan, R B Klisovic, D Perrotti, M A Caligiuri, J C Byrd, C-S Chen, L James Lee, S Jacob, K Mrózek, C D Bloomfield, W Blum, R Garzon, S Schwind & G Marcucci. (2012) Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia. Leukemia 27:4, pages 871-878.
Crossref
Crossref
Veronika V. Borutinskaite, Karl-Eric Magnusson & Ruta Navakauskiene. (2012) Histone deacetylase inhibitor BML-210 induces growth inhibition and apoptosis and regulates HDAC and DAPC complex expression levels in cervical cancer cells. Molecular Biology Reports 39:12, pages 10179-10186.
Crossref
Crossref
Rakel Brendsdal Forthun, Tanima SenGupta, Hanne Kim Skjeldam, Jessica Margareta Lindvall, Emmet McCormack, Bjørn Tore Gjertsen & Hilde Nilsen. (2012) Cross-Species Functional Genomic Analysis Identifies Resistance Genes of the Histone Deacetylase Inhibitor Valproic Acid. PLoS ONE 7:11, pages e48992.
Crossref
Crossref
Hanne Fredly, Håkon Reikvam, Bjørn Tore Gjertsen & Øystein Bruserud. (2012) Disease‐stabilizing treatment with all‐trans retinoic acid and valproic acid in acute myeloid leukemia: Serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti‐leukemic treatment. American Journal of Hematology 87:4, pages 368-376.
Crossref
Crossref
Wenjuan Yu, Jianxiang Wang, Jie Jin, Wenbin Qian, Jiejing Qian, Yizhi Cheng & Lei Wang. (2011) Heat shock protein 90 inhibition results in altered downstream signaling of mutant KIT and exerts synergistic effects on Kasumi-1 cells when combining with histone deacetylase inhibitor. Leukemia Research 35:9, pages 1212-1218.
Crossref
Crossref
Jianjun XieAndre LarochelleIrina MaricMarion FaulhaberRobert E. DonahueCynthia E. Dunbar. (2010) Repetitive Busulfan Administration After Hematopoietic Stem Cell Gene Therapy Associated with a Dominant HDAC7 Clone in a Nonhuman Primate. Human Gene Therapy 21:6, pages 695-703.
Crossref
Crossref
Astrid Olsnes Kittang, Kimberley Hatfield, Kristoffer Sand, Håkon Reikvam & Øystein Bruserud. 2010. The Chemokine System in Experimental and Clinical Hematology. The Chemokine System in Experimental and Clinical Hematology
149
172
.
Suzanne E. Wardell, Olga R. Ilkayeva, Heather L. Wieman, Daniel E. Frigo, Jeffrey C. Rathmell, Christopher B. Newgard & Donald P. McDonnell. (2009) Glucose Metabolism as a Target of Histone Deacetylase Inhibitors. Molecular Endocrinology 23:3, pages 388-401.
Crossref
Crossref
Anne M. Distler, Janos Kerner, Kwangwon Lee & Charles L. Hoppel. 2009. Mitochondrial Function, Part B: Mitochondrial Protein Kinases, Protein Phosphatases and Mitochondrial Diseases. Mitochondrial Function, Part B: Mitochondrial Protein Kinases, Protein Phosphatases and Mitochondrial Diseases
97
115
.
Akua K. Oduro, Michael K. Fritsch & Fern E. Murdoch. (2008) Chromatin context dominates estrogen regulation of pS2 gene expression. Experimental Cell Research 314:15, pages 2796-2810.
Crossref
Crossref
Matthias Körner & Ulrich Tibes. 2008. Progress in Medicinal Chemistry Volume 46. Progress in Medicinal Chemistry Volume 46
205
280
.
Bjørn Tore Gjertsen & Gry Sjøholt. 2008. Cancer Proteomics. Cancer Proteomics
161
187
.
K L Rice, I Hormaeche & J D Licht. (2007) Epigenetic regulation of normal and malignant hematopoiesis. Oncogene 26:47, pages 6697-6714.
Crossref
Crossref
Anita Ryningen, Camilla Stapnes & Øystein Bruserud. (2007) Clonogenic acute myelogenous leukemia cells are heterogeneous with regard to regulation of differentiation and effect of epigenetic pharmacological targeting. Leukemia Research 31:9, pages 1303-1313.
Crossref
Crossref
Anne M. Distler, Janos Kerner & Charles L. Hoppel. (2007) Post-translational modifications of rat liver mitochondrial outer membrane proteins identified by mass spectrometry. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 1774:5, pages 628-636.
Crossref
Crossref
Camilla Stapnes, Anne P. Døskeland, Kimberley Hatfield, Elisabeth Ersvær, Anita Ryningen, James B. Lorens, Bjørn Tore Gjertsen & Øystein Bruserud. (2007) The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. British Journal of Haematology 136:6, pages 814-828.
Crossref
Crossref
T C Karagiannis & A El-Osta. (2006) Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds?. Leukemia 21:1, pages 61-65.
Crossref
Crossref
N Ånensen, J Skavland, C Stapnes, A Ryningen, A-L Børresen-Dale, B T Gjertsen & Ø Bruserud. (2006) Acute myelogenous leukemia in a patient with Li–Fraumeni syndrome treated with valproic acid, theophyllamine and all-trans retinoic acid: a case report. Leukemia 20:4, pages 734-736.
Crossref
Crossref